Identification of the Key Genes Associated with Chemotherapy Sensitivity in Ovarian Cancer Patients

Overview

Journal Cancer Med

Specialty Oncology

Date 2020 May 23

PMID 32441484

Citations 5

Authors

Hui Zheng

Meiqin Zhang

Shuang Ma

Wenting Yang

Suhong Xie

Yanchun Wang

Yixuan Liu

Jinyan Kai

Qian Ma

Renquan Lu

Lin Guo

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer (OC) is the deadliest gynecological cancer. The absence of biomarkers in early detection and chemotherapy resistance is a principal cause of treatment failure in OC.

Methods: In this study, next generation sequencing (NGS) was used to sequence the mRNA of 44 OC patients including 14 chemotherapy insensitive and 18 sensitive patients. Differentially expressed genes (DEGs) from OC patients (compared with healthy controls) and chemotherapy sensitive patients (compared with chemotherapy insensitive patients) were identified by edgeR v3.12.0 in R v3.2.2, which were enriched using Gene Ontology (GO) database and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG). The common DEGs in cancer occurring and chemotherapy sensitivity were further screened. Among them, genes participating in chemotherapy sensitivity associated pathways were regarded as chemotherapy sensitivity-related key genes. Quantitative real-time PCR (qPCR) and immunohistochemistry (IHC) were used to verify the expression of the key genes.

Results: We found 1588 DEGs between OC patients and healthy controls (HCs), which were mainly enriched in cell cycle pathway. Meanwhile, 249 DEGs were identified between chemotherapy sensitive and insensitive OC patients, which were mainly enriched in MAPK signaling pathway, ERBB signaling pathway, TNF signaling pathway, and IL-17 signaling pathway. Thirty-five DEGs were shared in chemotherapy sensitivity group and cancer occurring group. Among them, there are five genes (JUND, JUNB, MUC5B, NRG1, and NR4A1) participating in the above four chemotherapy sensitivity-related pathways. It is remarkable that JUND is in the upstream of MUC5B in IL-17 signaling pathway and their expressions were verified by qPCR and IHC.

Conclusions: The expression levels of the key genes related to chemotherapy sensitivity might be used as biomarkers to predict the treatment outcome and as a target to improve prognosis.

Citing Articles

Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma.

Petrella S, Colombo M, Marabese M, Grasselli C, Panfili A, Chiappa M Int J Mol Sci. 2025; 26(2).

PMID: 39859203 PMC: 11765470. DOI: 10.3390/ijms26020472.

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.

Alam S, Giri P Cancer Drug Resist. 2024; 7:6.

PMID: 38434767 PMC: 10905178. DOI: 10.20517/cdr.2023.152.

bestDEG: a web-based application automatically combines various tools to precisely predict differentially expressed genes (DEGs) from RNA-Seq data.

Sangket U, Yodsawat P, Nuanpirom J, Sathapondecha P PeerJ. 2022; 10:e14344.

PMID: 36389403 PMC: 9657178. DOI: 10.7717/peerj.14344.

The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.

Drumond-Bock A, Bieniasz M Mol Cancer. 2021; 20(1):145.

PMID: 34758842 PMC: 8579545. DOI: 10.1186/s12943-021-01424-5.

Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study.

Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J Transl Lung Cancer Res. 2021; 10(7):3030-3042.

PMID: 34430345 PMC: 8350085. DOI: 10.21037/tlcr-21-201.

References

Ryseck R, Bravo R . c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins. Oncogene. 1991; 6(4):533-42. View

Sun J, Bao S, Xu D, Zhang Y, Su J, Liu J . Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. Cell Death Dis. 2019; 10(9):661. PMC: 6737147. DOI: 10.1038/s41419-019-1874-9. View

Zhang G, Liu H, Huang J, Wang L, Zhao J, Li C . TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Gynecol Oncol. 2014; 132(3):752-7. DOI: 10.1016/j.ygyno.2014.01.028. View

Liu G, Yang D, Rupaimoole R, Pecot C, Sun Y, Mangala L . Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015; 107(7). PMC: 4554255. DOI: 10.1093/jnci/djv108. View

Shang S, Yang J, Jazaeri A, Duval A, Tufan T, Lopes Fischer N . Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer. Cancer Res. 2019; 79(18):4599-4611. PMC: 6744966. DOI: 10.1158/0008-5472.CAN-19-0215. View

Beral V, DOLL R, Hermon C, Peto R, Reeves G . Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371(9609):303-14. DOI: 10.1016/S0140-6736(08)60167-1. View

Kankia I, Khalil H, Langdon S, Moult P, Bown J, Deeni Y . NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib. Oxid Med Cell Longev. 2018; 2017:1864578. PMC: 5749283. DOI: 10.1155/2017/1864578. View

Wilson A, Liu A, Roland J, Adebayo O, Fletcher S, Slaughter J . TR3 modulates platinum resistance in ovarian cancer. Cancer Res. 2013; 73(15):4758-69. PMC: 3944084. DOI: 10.1158/0008-5472.CAN-12-4560. View

Guo J, Pan H . Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972. Med Sci Monit. 2019; 25:9844-9854. PMC: 6938651. DOI: 10.12659/MSM.916820. View

10.

Yu Y, Zhang X, Tian H, Zhang Z, Tian Y . Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy. J BUON. 2018; 23(5):1396-1401. View

11.

Ramezani T, Nabiuni M, Baharara J, Parivar K, Namvar F . Sensitization of Resistance Ovarian Cancer Cells to Cisplatin by Biogenic Synthesized Silver Nanoparticles through p53 Activation. Iran J Pharm Res. 2019; 18(1):222-231. PMC: 6487401. View

12.

Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K . Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell. 2002; 14(4):305-15. View

13.

Liu Y, Yasukawa M, Chen K, Hu L, Broaddus R, Ding L . Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol. 2015; 1(4):486-94. PMC: 4608536. DOI: 10.1001/jamaoncol.2015.1432. View

14.

Chen S, Jiao J, Sun K, Zong Z, Zhao Y . MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther. 2015; 9:5225-35. PMC: 4577257. DOI: 10.2147/DDDT.S87526. View

15.

Liu Y, Niu Z, Lin X, Tian Y . MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Cancer Gene Ther. 2017; 24(5):208-214. DOI: 10.1038/cgt.2017.6. View

16.

Yang H, Mao W, Rodriguez-Aguayo C, Mangala L, Bartholomeusz G, Iles L . Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2018; 24(20):5072-5084. PMC: 6191368. DOI: 10.1158/1078-0432.CCR-18-0504. View

17.

Chen Y, Cao X, Li Y, Qiu Y, Li Y, Li W . Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer. Am J Physiol Cell Physiol. 2018; 315(2):C225-C235. DOI: 10.1152/ajpcell.00283.2017. View

18.

Teng C, Zheng H . Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer. Oncol Lett. 2017; 14(4):4277-4281. PMC: 5604148. DOI: 10.3892/ol.2017.6714. View

19.

Luo H, Wang X, Ge H, Zheng N, Peng F, Fu Y . Inhibition of ubiquitin‑specific protease 14 promotes connexin 32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells. Oncol Rep. 2019; 42(3):1237-1247. DOI: 10.3892/or.2019.7232. View

20.

Garcia-Vazquez R, Gallardo Rincon D, Ruiz-Garcia E, Meneses Garcia A, Hernandez de la Cruz O, Astudillo-de la Vega H . let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer. Oncol Rep. 2018; 39(6):3086-3094. DOI: 10.3892/or.2018.6366. View